SDS Biotech K.K. Reports Consolidated Earnings Results for the Six Months Ended September 30, 2016; Provides Consolidated Earnings Guidance for the Year Ending March 31, 2017
SDS Biotech K.K. reported consolidated earnings results for the six months ended September 30, 2016. For the quarter, the company reported net sales of ¥5,618 million against ¥7,242 million a year ago. Operating income was ¥183 million against ¥402 million a year ago. Ordinary income was ¥363 million against ¥231 million a year ago. Net income attributable to owners of parent was ¥127 million or ¥16.25 per basic share against ¥181 million or ¥23.13 per basic and diluted share a year ago. Net loss before income taxes and non-controlling interest was ¥362,860,000 compared to income of ¥232,027,000 a year ago. Net cash used in operating activities of ¥202,114,000 compared to ¥1,721,719,000 a year ago. Purchase of property, plant and equipment was ¥93,345,000 compared to ¥108,220,000 a year ago. Purchase of intangible assets was ¥17,013,000 compared to ¥30,369,000 a year ago.
For the fiscal year ending March 31, 2017, the consolidated company expects net sales of ¥16,210 million, operating income of ¥1,460 million, ordinary income of ¥1,220 million and net income of ¥820 million or ¥104.71 per share.